Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 13.6h

Persistency of Discharge Regimen by Follow-up Period, 2002 to 2006

Recipients with Heart-Lung Transplants

  Year of Transplant
2002 2003 2004 2005 2006
Discharge Regimen (w/ or w/o Steroid Use) CyA+Aza At Discharge (N) 6 4 5 10 3
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 33.3% 50.0% 60.0% 90.0% 50.0%
2 Years PostTx (%) 33.3% 25.0% 20.0% 30.0% -
3 Years PostTx (%) 33.3% 25.0% - - -
CyA+MMF At Discharge (N) 5 3 5 3 2
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 60.0% 66.7% 20.0% 100.0% 50.0%
2 Years PostTx (%) 60.0% 0.0% 20.0% 50.0% -
3 Years PostTx (%) 40.0% 0.0% - - -
Tac+Aza At Discharge (N) 4 5 5 2 1
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 100.0% 60.0% 60.0% 100.0% 100.0%
2 Years PostTx (%) 25.0% 40.0% 40.0% 100.0% 0.0%
3 Years PostTx (%) 25.0% 40.0% 40.0% - 0.0%
Tac+MMF At Discharge (N) 4 1 11 12 15
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 50.0% 0.0% 81.8% 58.3% 66.7%
2 Years PostTx (%) 0.0% 0.0% 54.5% 33.3% 66.7%
3 Years PostTx (%) 0.0% 0.0% 54.5% - -
Tac+Siro At Discharge (N) - - 1 - -
At Discharge (%) - - 100.0% - -
1 Year PostTx (%) - - 100.0% - -
2 Years PostTx (%) - - 100.0% - -
3 Years PostTx (%) - - - - -


Source: OPTN/SRTR Data as of May 1, 2008.

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.



PDF FormatRequires Adobe Acrobat Reader